Bayer Among Investors In $12M Funding For Edifice’s OTC Test For ‘Inflammatory Age’
Bayer led a $12m investment in Edifice Health, which plans to launch an OTC test kit to measure “inflammatory age” to help prevent chronic diseases. Consumer health R&D head Dave Evendon-Challis says the investment is in line with focus on deals for “big innovation jumps” in prevention.
You may also be interested in...
Bayer says its Consumer Health sales grew at twice the rate of the market in Q3, thanks to a number of operational changes instituted by business head Heiko Schipper back in 2018.
The Congressional Research Service published a dietary supplements report on 20 September that provides an overview of the industry and current regulatory issues, including ‘limitations’ in the US FDA’s authority over supplements and, in particular, the absence of mandatory product listing.
The Federal Trade Commission’s claim for monetary relief against the Prevagen memory supplement marketer is dismissed by a New York district court judge, who cites a recent Supreme Court decision gutting the FTC’s long-favored mechanism for collecting monies under the FTC Act.